Novosibirsk · Russian-qualified counsel Recognised by Pravo-300 · Best Lawyers · Kommersant
Tax

CFC rules and Russian tax residents in the pharmaceuticals sector: key developments in 2027

Kristina Kornouhova · July 2026 · 9 min read

Russian CFC rules for pharmaceutical sector tax residents saw significant tightening in 2027. Key developments for in-house counsel. Make an enquiry.

For pharmaceutical multinationals with Russian-resident holding or operating entities, the controlled foreign company rules applicable in Russia have, in the period to early 2027, developed in a direction that demands careful review of existing group structures. The Federal Tax Service has sharpened its focus on passive income flows — royalties, intercompany financing returns, and dividend income routed through intermediate jurisdictions — that are characteristic of multinational pharmaceutical groups. Russian tax residents who hold interests in foreign subsidiaries or IP-holding entities, and who have not revisited their CFC disclosure positions since the preceding reporting cycle, face meaningful exposure in an enforcement environment that has grown considerably more active.

§ I. What has changed in Russian CFC rules for 2027?

The Russian controlled foreign company framework, established in federal tax legislation and progressively refined through FTS guidance and court decisions, has undergone further development entering 2027. The principal shift — consistent with the trajectory of the preceding two years — concerns the qualification and attribution of passive income in structures where a Russian tax resident holds, directly or indirectly, a participation interest in a foreign company.

Two developments are particularly relevant for pharmaceutical sector structures. First, the approach of the Federal Tax Service to the "active income" exemption has tightened. Pharmaceutical groups frequently argue that foreign IP-holding or licensing subsidiaries qualify for the active exemption on the basis that their activities constitute genuine economic substance. The FTS has, in its audit and pre-litigation correspondence observed during this period, applied a narrower reading of what constitutes qualifying activity — in particular scrutinising whether the foreign entity has sufficient headcount, decision-making autonomy, and operational infrastructure to sustain the exemption claim. The burden, in practice, falls on the Russian tax resident to demonstrate substance rather than on the FTS to disprove it.

Second, the interplay between the CFC rules and Russian transfer pricing legislation has become a more prominent point of contention. Where a Russian pharmaceutical entity makes royalty payments to a foreign affiliate, and that affiliate is a controlled foreign company for Russian tax purposes, the FTS has taken the position — in a number of administrative proceedings — that the transfer pricing analysis and the CFC income attribution analysis are not mutually exclusive. Both instruments may be applied concurrently, creating a risk of economic double counting that is difficult to challenge without comprehensive contemporaneous documentation.

For in-house counsel managing a Russian pharmaceutical subsidiary whose group structure includes foreign IP-holding, licensing, or financing entities, the regulatory timeline for the 2027 reporting cycle — with notification and profit declaration obligations arising within defined windows after the tax period closes — leaves limited margin for delay in reviewing current positions.

If your Russian subsidiary has CFC notification or profit declaration obligations arising from the 2027 reporting period, contact the team now: info@vetrovpartners.com |

§ II. Which pharmaceutical sector structures are most exposed?

Not every pharmaceutical group with a Russian tax-resident entity faces equal exposure under the current CFC enforcement environment. The risk profile is materially shaped by the type of foreign entity held and the nature of the income flows involved.

IP-holding structures. The most commonly challenged arrangement in the pharmaceutical sector involves a Russian operating entity that holds — directly or through an intermediate holding company — a foreign subsidiary that owns intellectual property: patents, data exclusivity rights, or know-how. Royalty income received by that foreign subsidiary from the Russian entity or from third parties in other jurisdictions is typically passive income for CFC purposes. Where the foreign subsidiary cannot demonstrate qualifying active-business substance, the profit of that subsidiary is attributed to the Russian shareholder and subject to Russian profits tax, regardless of whether it has been distributed.

Intragroup financing entities. Russian pharmaceutical groups and foreign groups with Russian operating arms frequently use dedicated finance subsidiaries to channel intercompany loans. Interest income is passive income under the Russian CFC framework. Finance subsidiaries in low-tax jurisdictions — even those that were previously tolerated under earlier FTS administrative practice — are increasingly the subject of audit queries that treat the interest margin as attributable CFC profit. The relevant threshold for CFC profit attribution has remained unchanged in the legislation, but the FTS's willingness to pursue attribution at smaller profit levels has increased.

Distribution subsidiaries in EAEU member states. An important qualification applies to pharmaceutical distributors operating within the Eurasian Economic Union. Russian CFC legislation contains provisions treating income of foreign companies resident in EAEU member states differently from income of entities in third jurisdictions. However, this exemption is subject to conditions — including that the foreign entity is not interposed artificially — and the FTS has challenged its application in a number of pharmaceutical distribution structures where the EAEU subsidiary is thinly staffed or operationally integrated with the Russian parent to a degree that undermines the independence argument.

Understanding which category a particular foreign entity falls into — and whether the documentation currently available to the Russian tax-resident shareholder is sufficient to support the position taken on notification and profit declaration — is the threshold question for any group undertaking a review.

The firm's Tax Controversy practice has advised pharmaceutical groups and their holding entities on CFC exposure assessments and FTS audit responses across a range of structures. Related analysis of how Russian courts approach CFC rules and Russian tax residents is available at How Russian courts approach CFC rules and Russian tax residents, and strategic considerations for planning CFC positions are set out at Strategic considerations in CFC rules and Russian tax residents.

For pharmaceutical groups that have recently restructured — whether in response to regulatory changes in the sector or as part of a broader group reorganisation — a targeted CFC position review conducted ahead of the FTS audit cycle provides the most effective risk-management outcome. Cases identified through the firm's Matters records suggest that the cost of early-stage advisory work is materially lower than the cost of contesting attributions after an audit notice has been issued.

"The defining feature of the current FTS approach to pharmaceutical CFC structures is not the legislation itself — which has been stable in its core architecture — but the quality of scrutiny applied to substance claims. Clients who documented their positions thoroughly two years ago should not assume that documentation remains adequate today."

— Kristina Kornouhova, Senior Lawyer, Practice Lead — Tax & Antitrust, Vetrov & Partners

To discuss CFC exposure in your Russian pharmaceutical or holding structure, make an enquiry: info@vetrovpartners.com |

§ III. What should foreign in-house counsel do now?

The practical steps available to in-house counsel managing a Russian entity's CFC position depend on where in the compliance cycle the group currently sits. Three distinct situations arise.

Before the notification deadline. If the group has not yet submitted CFC notifications for the relevant period, the priority is to confirm which foreign entities meet the CFC threshold for Russian tax purposes, whether any exemptions apply, and whether the documentation supporting any exemption claim is current and complete. The notification obligation arises regardless of whether CFC profit is ultimately attributed — non-notification carries its own penalty exposure, separate from the profit attribution analysis.

After notification but before the profit declaration. Groups that have submitted notifications but have not yet finalised their CFC profit calculation have an opportunity to review whether the active-income exemption position — or any other basis for excluding CFC profit — is supported by the substance evidence currently available. For pharmaceutical IP-holding entities in particular, it is worth assessing whether any developments during the tax period (staff changes, changes in licensing agreements, shifts in operational control) have affected the substance position.

Under active FTS audit. Where a Russian pharmaceutical entity has received an audit notice that includes a CFC-related query, the response strategy requires careful coordination between the Russian tax function and group treasury or IP management. The FTS audit timeline under Russian tax procedure is defined, and the windows for submitting objections and requesting additional time are not extendable at will. Early involvement of specialist counsel — rather than routing all communications through the general corporate team — typically produces better outcomes in terms of the quality and coherence of the factual record presented to the FTS.

Across all three situations, the common thread is documentation quality. Russian CFC rules and their application by the FTS in the pharmaceutical sector reward groups that treat CFC compliance as an ongoing documentation exercise rather than a year-end filing task. The most effective preparation for a potential Russia law update on CFC rules — including any further tightening that may follow from the 2027 regulatory cycle — is a CFC compliance framework that is stress-tested against current FTS audit themes rather than against the legislation as originally enacted.

Frequently asked questions

Q: What specifically changed in how the FTS applies Russian CFC rules in 2027?

A: The most significant development entering 2027 is the tightening of the FTS's approach to the active-income exemption and the concurrent application of CFC profit attribution and transfer pricing adjustments. The FTS has applied a more demanding substance test to foreign entities claiming the active exemption — particularly in pharmaceutical IP-holding and licensing structures — requiring evidence of genuine operational autonomy, headcount, and decision-making capacity. In parallel, the FTS has taken the position in a number of administrative proceedings that transfer pricing and CFC attribution may be applied simultaneously to the same intercompany flow, increasing the aggregate tax exposure where documentation does not clearly address both instruments.

Q: Which Russian pharmaceutical sector entities are most affected by the 2027 CFC developments?

A: Russian tax-resident entities — whether Russian incorporated subsidiaries of foreign groups or Russian holding companies — that hold interests in foreign IP-owning, licensing, or financing subsidiaries face the highest exposure. Distribution subsidiaries in EAEU member states are also affected, though different exemption conditions apply. Groups with thinly staffed foreign affiliates, or where the operational substance of a foreign entity has diminished since it was originally structured, are at greatest risk of FTS challenge. In-house counsel at pharmaceutical multinationals should treat any foreign entity receiving royalties from or making intercompany loans to a Russian affiliate as a priority for CFC position review.

Q: What should in-house counsel do immediately to manage Russian CFC risk in a pharmaceutical structure?

A: The immediate priority is to confirm whether the Russian entity has met its CFC notification obligations for the current period and to assess whether the documentation supporting any active-income exemption or other exclusion claim is current. For entities under active FTS audit, early involvement of specialist Russian tax counsel is advisable given the defined procedural deadlines under Russian tax procedure. Where restructuring has occurred within the group during the tax period — whether for regulatory or commercial reasons — those changes should be mapped against the CFC substance requirements before the profit declaration is finalised.

Practitioner note

This briefing is general information and does not constitute legal advice. For advice on a specific matter, write in confidence to info@vetrovpartners.com.

Facing a matter like this?

Our team advises foreign clients on exactly these questions across Russia and the EAEU region. Initial 30-minute consultation — complimentary.

Make an enquiry